Advertisement.
Advertisement.
Advertisement
Advertisement.
CASI CASI Pharmaceuticals Inc
6,019
| Market Cap | $88.78M |
| Volume | 18,752.00 |
| 52-Wk High | $8.48 |
| 52-Wk Low | $1.90 |
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
PR Newswire•7 days ago
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS PR Newswire BEIJING, July 19, 2024...
Share to Feed
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP PR Newswire BEIJING, July 8, 2024 BEIJING...
PR Newswire•19 days ago
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China...
PR Newswire•1 month ago
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He CASI Pharmaceuticals Announces $15...
PR Newswire•1 month ago
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) CASI Pharmaceuticals Receives FDA Clearance On The...
PR Newswire•2 months ago
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS PR Newswire BEIJING, May 14, 2024...
PR Newswire•2 months ago
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS PR Newswire BEIJING, April 8, 2024...
PR Newswire•4 months ago
Stock analysts at StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI - Get Free Report) in a note issued to investors on Friday. The firm set a "hold" rating on the...
Zolmax•4 months ago
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS PR...
PR Newswire•4 months ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth...
InvestorPlace•4 months ago